Philogen Announces Research Collaboration with Servier in the Field of DNA-Encoded Chemistry
Philogen S.p.A., a privately owned biotechnology company, today announced through its wholly owned Swiss subsidiary, Philochem AG, a collaboration with Servier to discover new small molecule-based therapeutics using Philochem’s proprietary ESAC platform and DNA-Encoded Chemistry technology.
“We are extremely pleased to establish a new collaboration with Servier, one of the largest independent pharmaceutical groups worldwide, with a great tradition in small-molecule based therapeutics. We hope our DNA-Encoded Chemistry technology and ESAC platform will contribute to bring innovative treatment for serious unmet medical needs.” commented Prof. Dario Neri, co-founder and President of the Scientific Advisory Board of Philogen.
No financial details of the agreement were released.
About the Philogen group
Philogen is a Swiss-Italian clinical-stage company engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen’s strategy is to deliver bioactive agents, for example cytokines or drugs, to the site of disease using antibodies and other ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned, and has signed agreements with several major pharmaceutical companies. For more information please visit www.philogen.com .
About Philochem’s ESAC platform and DNA-Encoded Chemistry technology
The proprietary ESAC platform and DNA-Encoded Chemistry technology were developed by Philochem scientists in collaboration with the group of Prof. Dario Neri at ETH Zurich during the past decade. These two powerful and complementary discovery technologies allow to screen up to billions small molecules compounds in a very fast and efficient manner, and to further optimize the hit compounds in a fully automatic, DNA-tagged, fragment-based drug discovery manner.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Business Wire
IPSEN19.9.2017 18:03 | pressemeddelelse
Ipsen Receives Approval from European Commission for Xermelo® (Telotristat Ethyl) for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy
CA-PATIENT-SAFETY-MVMNT19.9.2017 17:02 | pressemeddelelse
6th Annual World Patient Safety, Science & Technology Summit to Be Held in London, England
MA-VERTEX19.9.2017 16:52 | pressemeddelelse
Vertex Announces Upcoming Presentations of Data at 2017 North American Cystic Fibrosis Conference
DELTICOM-AG19.9.2017 15:59 | pressemeddelelse
Biker Summer 2017 campaign: Last Chance to Win Great Prizes from Moto-tyres.co.uk
CA-ANDERSEN-TAX19.9.2017 15:32 | pressemeddelelse
Andersen Global Expands into Uruguay
HORIZON-PETROLEUM19.9.2017 15:07 | pressemeddelelse
Horizon Petroleum Enters into Definitive Agreements to Acquire Concessions in Poland
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum